We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.19B
AUM Growth
-$83.9M
Cap. Flow
-$366M
Cap. Flow %
-11.48%
Top 10 Hldgs %
36.17%
Holding
103
New
17
Increased
19
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$71.8M
2
CNC icon
Centene
CNC
+$35.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$34M
4
GH icon
Guardant Health
GH
+$22.8M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$22.5M

Top Sells

Rank Stock Value
1
PPD
PPD, Inc. Common Stock
PPD
+$41.5M
2
AZN icon
AstraZeneca
AZN
+$33M
3
PODD icon
Insulet
PODD
+$30.9M
4
GILD icon
Gilead Sciences
GILD
+$27.3M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$27.2M

Sector Composition

Rank Sector Weight
1 Healthcare 91.64%
2 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNST
51
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$15.9M 0.5%
469,664
– –
ALLO icon
52
Allogene Therapeutics
ALLO
$649M
$15.8M 0.5%
606,800
+16,422
+3% +$468K
ADAP
53
DELISTED
Adaptimmune Therapeutics
ADAP
$15.5M 0.48%
3,627,900
+1,126,597
+45% +$5.47M
ACAD icon
54
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
$14.7M 0.46%
+602,100
New +$13.6M
NTLA icon
55
CALL
Intellia Therapeutics
NTLA
$1.49B
$13.8M 0.43%
+85,000
New +$6.62M
AZN icon
56
AstraZeneca
AZN
$263B
$12.5M 0.39%
104,300
-300,900
-74% -$33M
LFST icon
57
Lifestance Health
LFST
$4B
$12.4M 0.39%
+443,595
New +$11.7M
BCRX icon
58
BioCryst Pharmaceuticals
BCRX
$2.28B
$11.2M 0.35%
+708,927
New +$9.63M
PRDS
59
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$10M 0.31%
1,000,000
– –
PMVP icon
60
PMV Pharmaceuticals
PMVP
$59.2M
$9.85M 0.31%
+288,334
New +$9.63M
STTK icon
61
Shattuck Labs
STTK
$675M
$9.47M 0.3%
326,813
– –
INNV icon
62
InnovAge Holding
INNV
$1.54B
$9.16M 0.29%
429,699
– –
PRAX icon
63
Praxis Precision Medicines
PRAX
$8.58B
$8.32M 0.26%
+30,358
New +$10.9M
VECT
64
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$7.13M 0.22%
+611,074
New +$9.28M
HOWL icon
65
Werewolf Therapeutics
HOWL
$17.2M
$6.98M 0.22%
+400,000
New +$5.48M
LONA
66
LeonaBio Inc
LONA
$66.3M
$6.95M 0.22%
67,825
+20,802
+44% +$3.63M
KNTE
67
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$6.15M 0.19%
264,293
– –
LAB icon
68
Standard BioTools
LAB
$340M
$6.04M 0.19%
980,505
– –
LUNG icon
69
Pulmonx
LUNG
$68.8M
$6.03M 0.19%
136,576
– –
SPRY icon
70
ARS Pharmaceuticals
SPRY
$509M
$5.82M 0.18%
188,243
– –
ONEM
71
DELISTED
1Life Healthcare
ONEM
$5.68M 0.18%
171,689
– –
CYTK icon
72
CALL
Cytokinetics
CYTK
$10.5B
$5.32M 0.17%
+268,600
New +$6.31M
BLSA
73
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.89M 0.15%
464,103
– –
JYAC
74
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.61M 0.14%
464,103
– –
CERT icon
75
Certara
CERT
$1.26B
$4.05M 0.13%
143,028
-115,133
-45% -$3.2M
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q2 2021 Portfolio in Review

As of Q2 2021, PFM Health Sciences held 103 positions worth $3.19B, down 2.6% from $3.27B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

PFM Health Sciences withdrew a net $366M in Q2 2021, closing 19 positions and reducing 13 holdings. Its most notable exit was PPD, Inc. Common Stock, an estimated $41.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Financials.

Against the trend, PFM Health Sciences opened a new position in Seagen Inc. Common Stock worth $76.3M.

  • PFM Health Sciences's largest Q2 2021 buy was Seagen Inc. Common Stock: 482,985 shares worth $76.3M.
  • PFM Health Sciences added most to Centene in Q2 2021, an estimated $35.1M increase.
  • PFM Health Sciences's biggest Q2 2021 reduction was AstraZeneca, cutting an estimated $33M.
  • PFM Health Sciences fully exited PPD, Inc. Common Stock in Q2 2021, selling an estimated $41.5M.
  • PFM Health Sciences's ten largest holdings make up 36% of its $3.19B portfolio in Q2 2021.
  • PFM Health Sciences opened 17 new positions and closed 19 in Q2 2021.
  • PFM Health Sciences's portfolio value fell 2.6% quarter-over-quarter to $3.19B.

Based on PFM Health Sciences's 13F filing for Q2 2021, filed 16 Aug 2021.